-transparent.png){kind=logo}
Between 1970-78, 302 mitral valve replacements with the SE 6120 prosthesis were performed, with an average postoperative follow-up of 50,7 months, using the 3 M size (206 cases) and 2 M (96 cases with small left ventricles). Early postoperative mortality was 5,6%, late postoperative mortality: 17,2%, the 5 year actuarial survival rate: 77,4% and the 9 year survival rate 71,8% (early mortality included). There was no significant difference in survival after mono- (143 cases) and polyvalvular replacement (159 cases); only a voluminous left atrium (p less than 0,05) and left atrial thrombosis (p less than 0,01) were statistically significant prognostic factors of global mortality. Late haemorrhage due to anticoagulant therapy (3%) (0,6 per 100 patient years). The most common complication was systemic embolism (3,7 per 100 patient years). Actuarial studies showed that 86,6% at 5 years and 80,1% at 9 years, escaped this complication. Statistically the favorising roles of permanent atrial fibrillation (p less than 0,05), the size of the left atrium (p less than 0,02) of isolated demonstrated. 90,4% of the survivors were clinically improved: the functional result was better when that 86,6% at 5 years and 80,1% at 9 years, escaped this complication. Statistically the favorising roles of permanent atrial fibrillation (p less than 0,05), the size of the left atrium (p less than 0,02) of isolated demonstrated. 90,4% of the survivors were clinically improved: the functional result was better when that 86,6% at 5 years and 80,1% at 9 years, escaped this complication. Statistically the favorising roles of permanent atrial fibrillation (p less than 0,05), the size of the left atrium (p less than 0,02) of isolated demonstrated. 90,4% of the survivors were clinically improved: the functional result was better when the valve replacement was not a reoperation (p less than 0,02), when the patient was not in functional Class IV (p less than 0,01), in permanent excessively dilated (p less than 0,01) and in patients without severe tricuspid regurgitation (p less than 0,01). There was no significant difference in global mortality, the percentage of embolic events and the quality of the functional postoperative result between patients with the 3 M and those with the 2 M SE 6120 prosthesis.
P Mikaeloff, and
P Van Haecke, and
J P Frieh, and
G Convert, and
A Biron, and
C Amouroux, and
J Boivin
July 1972,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
P Mikaeloff, and
P Van Haecke, and
J P Frieh, and
G Convert, and
A Biron, and
C Amouroux, and
J Boivin
June 1994,
[Zasshi] [Journal]. Nihon Kyobu Geka Gakkai,
P Mikaeloff, and
P Van Haecke, and
J P Frieh, and
G Convert, and
A Biron, and
C Amouroux, and
J Boivin
October 1973,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
P Mikaeloff, and
P Van Haecke, and
J P Frieh, and
G Convert, and
A Biron, and
C Amouroux, and
J Boivin
February 1991,
Annales de cardiologie et d'angeiologie,
P Mikaeloff, and
P Van Haecke, and
J P Frieh, and
G Convert, and
A Biron, and
C Amouroux, and
J Boivin
October 1967,
Diseases of the chest,
P Mikaeloff, and
P Van Haecke, and
J P Frieh, and
G Convert, and
A Biron, and
C Amouroux, and
J Boivin
March 1993,
The Journal of heart valve disease,
P Mikaeloff, and
P Van Haecke, and
J P Frieh, and
G Convert, and
A Biron, and
C Amouroux, and
J Boivin
November 1982,
The Journal of thoracic and cardiovascular surgery,
P Mikaeloff, and
P Van Haecke, and
J P Frieh, and
G Convert, and
A Biron, and
C Amouroux, and
J Boivin
February 1976,
The Journal of thoracic and cardiovascular surgery,
P Mikaeloff, and
P Van Haecke, and
J P Frieh, and
G Convert, and
A Biron, and
C Amouroux, and
J Boivin
January 1971,
Acta cardiologica,
P Mikaeloff, and
P Van Haecke, and
J P Frieh, and
G Convert, and
A Biron, and
C Amouroux, and
J Boivin
March 2006,
The American journal of cardiology,
